Connaught Fund
Activation of central GLP-1 receptors enhances neuronal insulin signaling, improves glucose uptake, and supports mitochondrial energy production
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Join the conversation
How to use Saxenda
For instance, artichoke leafderived CQDs showed effective dose-dependent anticancer activity in MCF-7 cells, with an IC 50 of 96.5 g/mL, while retaining strong fluorescence properties, thereby demonstrating dual utility in bioimaging and cytotoxicity-based research [156]
Victoza is FDA-approved to help control blood sugar in type 2 diabetes and can also support weight loss off-label
